Joanne Cox

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Stephen Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer · 2019 · 650 citations · Full text

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Hope S. Rugo, Jens Huober, José Á. García-Sáenz et al. · The Oncologist · 2020 · 158 citations · Full text

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Saroj Vadhan‐Raj, Rafat Abonour, Jonathan W. Goldman et al. · Journal of Hematology & Oncology · 2017 · 83 citations · Full text

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Hope S. Rugo, Jens Huober, José Á. García-Sáenz et al. · The Oncologist · 2021 · 27 citations · Full text

Breast Oncology, Cancer Management, Pathology +21

Abstract GS1-01: Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer

Joyce O’Shaughnessy, Stephen Johnston, Nadia Harbeck et al. · Cancer Research · 2021 · 13 citations

Primary Outcome Analysis, Surgical Oncology, Breast Oncology +18